TY - JOUR T1 - Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation JF - BMJ Case Reports JO - BMJ Case Reports DO - 10.1136/bcr-2021-241634 VL - 14 IS - 5 SP - e241634 AU - Darren Wong AU - William Thomas AU - Andrew Butler AU - Lisa Sharkey Y1 - 2021/05/01 UR - http://casereports.bmj.com/content/14/5/e241634.abstract N2 - A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis. ER -